Tags

Type your tag names separated by a space and hit enter

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
HIV Med. 2005 May; 6(3):198-205.HM

Abstract

OBJECTIVES

To determine the factors associated with clinical progression (AIDS events and death) in antiretroviral-naive patients who have begun highly active antiretroviral therapy (HAART).

METHODS

HIV-infected patients naive to antiretroviral therapy were included in a prospective hospital-based cohort who began HAART between June 1996 and December 2001. Progression was explained by baseline characteristics using Cox proportional hazards models.

RESULTS

Overall, data for 709 patients were analysed. In multivariate analysis, factors associated with an increased risk of progression were CD4 count < 50 cells/microL [hazard ratio (HR) = 13.0 (95% confidence interval 3.8-44.3)] and between 50 and 199 cells/microL [HR = 5.1 (1.6-16.3)], when compared with patients with CD4 count>350 cells/microL; AIDS events before HAART prescription [HR = 2.1 (1.2-3.7)]; CD8 count < 400 cells/microL [HR = 1.8 (1.1-3.0)]; and older age (HR = 1.2 by 10 years (1.0-1.5)]. In a second model including CD4 percentage, factors associated with progression were CD4 < 10% [HR = 6.3 (2.2-17.9)] and 10%<CD4 < 15% [HR = 4.2 (1.4-12.5)], when compared with patients with CD4 > 20%; CD8 count; AIDS events before HAART prescription; and older age. In a third model including the CD4:CD8 ratio, factors associated with progression were CD4:CD8 < 15% [HR = 8.2 (2.3-28.8)] and 15% < CD4:CD8 < 30% [HR = 4.6 (1.3-16.0)], when compared with patients with CD4:CD8 > 45%; AIDS events before HAART prescription; and older age. The Akaike information criteria for model analysis were 803, 805 and 815, respectively.

CONCLUSIONS

Consideration of CD4 level in terms of CD4:CD8 ratio or CD4 percentage can be a good alternative to absolute CD4 count. Other prognostic factors such as older age, CD8 count < 400 cells/microL and AIDS events also have to be considered in the decision to initiate HAART.

Authors+Show Affiliations

Department of Internal Medicine and Infectious Diseases, Saint-André Hospital, Bordeaux University Hospital, Bordeaux, France. fbonnet@nchecr.unsw.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15876287

Citation

Bonnet, F, et al. "Determinants of Clinical Progression in Antiretroviral-naive HIV-infected Patients Starting Highly Active Antiretroviral Therapy. Aquitaine Cohort, France, 1996-2002." HIV Medicine, vol. 6, no. 3, 2005, pp. 198-205.
Bonnet F, Thiébaut R, Chêne G, et al. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med. 2005;6(3):198-205.
Bonnet, F., Thiébaut, R., Chêne, G., Neau, D., Pellegrin, J. L., Mercié, P., Beylot, J., Dabis, F., Salamon, R., & Morlat, P. (2005). Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Medicine, 6(3), 198-205.
Bonnet F, et al. Determinants of Clinical Progression in Antiretroviral-naive HIV-infected Patients Starting Highly Active Antiretroviral Therapy. Aquitaine Cohort, France, 1996-2002. HIV Med. 2005;6(3):198-205. PubMed PMID: 15876287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. AU - Bonnet,F, AU - Thiébaut,R, AU - Chêne,G, AU - Neau,D, AU - Pellegrin,J-L, AU - Mercié,P, AU - Beylot,J, AU - Dabis,F, AU - Salamon,R, AU - Morlat,P, AU - ,, PY - 2005/5/7/pubmed PY - 2005/9/21/medline PY - 2005/5/7/entrez SP - 198 EP - 205 JF - HIV medicine JO - HIV Med VL - 6 IS - 3 N2 - OBJECTIVES: To determine the factors associated with clinical progression (AIDS events and death) in antiretroviral-naive patients who have begun highly active antiretroviral therapy (HAART). METHODS: HIV-infected patients naive to antiretroviral therapy were included in a prospective hospital-based cohort who began HAART between June 1996 and December 2001. Progression was explained by baseline characteristics using Cox proportional hazards models. RESULTS: Overall, data for 709 patients were analysed. In multivariate analysis, factors associated with an increased risk of progression were CD4 count < 50 cells/microL [hazard ratio (HR) = 13.0 (95% confidence interval 3.8-44.3)] and between 50 and 199 cells/microL [HR = 5.1 (1.6-16.3)], when compared with patients with CD4 count>350 cells/microL; AIDS events before HAART prescription [HR = 2.1 (1.2-3.7)]; CD8 count < 400 cells/microL [HR = 1.8 (1.1-3.0)]; and older age (HR = 1.2 by 10 years (1.0-1.5)]. In a second model including CD4 percentage, factors associated with progression were CD4 < 10% [HR = 6.3 (2.2-17.9)] and 10%<CD4 < 15% [HR = 4.2 (1.4-12.5)], when compared with patients with CD4 > 20%; CD8 count; AIDS events before HAART prescription; and older age. In a third model including the CD4:CD8 ratio, factors associated with progression were CD4:CD8 < 15% [HR = 8.2 (2.3-28.8)] and 15% < CD4:CD8 < 30% [HR = 4.6 (1.3-16.0)], when compared with patients with CD4:CD8 > 45%; AIDS events before HAART prescription; and older age. The Akaike information criteria for model analysis were 803, 805 and 815, respectively. CONCLUSIONS: Consideration of CD4 level in terms of CD4:CD8 ratio or CD4 percentage can be a good alternative to absolute CD4 count. Other prognostic factors such as older age, CD8 count < 400 cells/microL and AIDS events also have to be considered in the decision to initiate HAART. SN - 1464-2662 UR - https://www.unboundmedicine.com/medline/citation/15876287/Determinants_of_clinical_progression_in_antiretroviral_naive_HIV_infected_patients_starting_highly_active_antiretroviral_therapy__Aquitaine_Cohort_France_1996_2002_ L2 - https://doi.org/10.1111/j.1468-1293.2005.00290.x DB - PRIME DP - Unbound Medicine ER -